Regeneron profits double ahead of $800 million expansion

//Regeneron profits double ahead of $800 million expansion

Regeneron profits double ahead of $800 million expansion

Regeneron Pharmaceuticals profits doubled to $2.44 billion last year amid growing demand for medications that treat eye disease, asthma and eczema. Sales of macular degeneration drug Eylea grew 10 percent to $4.08 billion in the United States. Meanwhile, U.S. sales of asthma and eczema medication Dupixent tripled last year to $776.3 million. The drug developer's growth fueled last year's decision to move forward with an $800 million manufacturing expansion in East Greenbush, New York, a few miles…

Article by [author-name] (c) Manufacturing News - Manufacturing News Headlines | Bizjournals.com - Read full story here.

By | 2019-02-07T11:00:00+00:00 February 7th, 2019|Budget and Tax|

About the Author: